Cingulate Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cingulate Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 3.30 $ to 11.70 $ · Last price: 4.80 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Cingulate Inc CING | 0.1 | – | -0.4 | – | 0.0 | – | 32.1 |
| Vertex Pharmaceuticals Inc VRTX | 133.1 | 31.9 | 24.4 | 55.0 | 38.1 | 9.6 | 37.8 |
| Regeneron Pharmaceuticals Inc REGN | 81.9 | 19.8 | 13.5 | 44.5 | 20.7 | 1.0 | 38.7 |
| Moderna Inc MRNA | 78.9 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| argenx NV ARGX | 59.7 | 36.7 | 31.5 | 59.1 | 32.0 | 89.6 | 31.9 |
| Revolution Medicines Inc RVMD | 42.6 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.0 |
| BeiGene, Ltd. ONC | 40.8 | 64.4 | 32.4 | 88.9 | 19.1 | 40.2 | 9.1 |
| Alnylam Pharmaceuticals Inc ALNY | 34.0 | 64.4 | 28.6 | 79.7 | 23.0 | 65.2 | -45.6 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 42.6 | 34.3 | 19.2 | 57.0 | 20.7 | 7.3 | 37.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -12 | -12 | -8.17 | -10 | 1 | 5 |
| 2020 | 0 | -7 | -7 | -5.08 | -7 | 1 | 6 |
| 2021 | 0 | -21 | -21 | -14.65 | -10 | 21 | 23 |
| 2022 | 0 | -18 | -18 | -12.63 | -16 | 4 | 11 |
| 2023 | 0 | -23 | -24 | -10.40 | -15 | -7 | 3 |
| 2024 | 0 | -16 | -17 | -4.34 | -18 | 7 | 15 |
| 2025 | 0 | -20 | -22 | -4.13 | -17 | 3 | 15 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q1 | -19.20 | 77.10 | -3,850 | -200.00 | – | -9 | -9 |
| 2024: Q2 | -5.47 | 96.00 | 0 | – | – | -2 | -2 |
| 2024: Q3 | -1.83 | 97.50 | 0 | – | – | -4 | -4 |
| 2025: Q1 | -1.04 | 94.60 | 0 | 100.00 | – | -5 | -5 |
| 2025: Q2 | -1.14 | 79.20 | 0 | – | – | -5 | -5 |
| 2025: Q3 | -1.35 | 26.20 | 0 | – | – | -4 | -4 |
| 2025: Q4 | -0.84 | 77.20 | 0 | -100.00 | – | -4 | -4 |
| 2026: Q1 | -0.95 | 8.70 | 0 | – | – | -7 | -7 |
| 2026: Q2 | -0.45 | 60.50 | – | – | – | -6 | -6 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.19 | -2.38 – -2.04 | 0 | 50.7% | 4 |
| 12/31/2027 | -0.88 | -2.30 – 1.81 | 22 | 59.8% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -894.8%
- ROCE > 15% -418.9%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Cingulate Inc., ein biopharmazeutisches Unternehmen, entwickelt mithilfe seiner Wirkstofffreisetzungsplattform-Technologie Arzneimittel zur Behandlung von Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) und Angststörungen in den Vereinigten Staaten. Der führende Produktkandidat des Unternehmens ist CTx-1301 (Dexmethylphenidat), der sich in klinischen Phase-3-Studien zur Behandlung von ADHS bei Kindern, Jugendlichen und Erwachsenen befindet. Es entwickelt zudem CTx-2103 (Buspiron), das sich im Formulierungsstadium zur Behandlung von Angststörungen befindet. Zudem plant das Unternehmen, einen klinischen Plan für CTx-1302 (Dextroamphetamin) zur Behandlung von ADHS einzuleiten. Cingulate Inc. wurde 2012 gegründet und hat seinen Hauptsitz in Kansas City, Kansas.
- Employees
- 14
- Headquarters
- Kansas City, KS
- Address
- 1901 West 47th Place, 66205 Kansas City, United States
- Phone
- 913 942 2300
- Website
- cingulate.com
- IPO Date
- 12/08/2021
- ISIN
- US17248W3034
- Stock Split
- 1:12 on 08/09/2024
- Stock Split
- 1:20 on 11/30/2023
Management
| Name | Title | Birth Year |
|---|---|---|
| Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Chairman of the Board | 1975 |
| Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer | 1964 |
| Jennifer L. Callahan CPA | Executive VP, CFO & Secretary | 1971 |
| Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer | 1958 |
| Thomas Dalton | Vice President of Investor & Public Relations | – |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/13/2026 Cingulate Inc. (CING): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.